​

Our CEO Sameer Agarwal announced in March this year a strategic alliance of CSA Healthcare GmbH with

✔︎ BlueJet Consulting (Laurent Decory)

✔︎ About Dots (Cruz López)

✔︎ Krüger CFO Services Consulting (Anders Krüger)

Sameer said, "These strategic alliances will enable us p...

Our CEO (Sameer Agarwal) will be presenting on June 14, 2019 at the BPI (Bundesverband der pharmazeutischen Industrie) meeting of the Committee on International Business.

His presentation will focus on "Portfolio & Market Entry Strategies for South East Asia". We are lo...

Our CEO, Sameer Agarwal, will be conference chair and will also make a presentation on Criteria to drive a high valuable portfolio. This conference, organized by marcusevans, has an excellent agenda with an outstanding group of speakers and moderators. Please let us kn...

Our CEO, Sameer Agarwal, was the conference chair and a key note speaker at Global Commercial and Sales Force Effectiveness Summit organised by KP-Morgan group. The Summit had relevant topics and an excellent panel of speakers from Pharma, Med-Tech and FMCG.

This is an outstanding article by Dr. Luca Dezzani on very important topic of barriers to drug development, the biggest one being the costs of clinical trials. Highly recommended for all colleagues involved in pharma / life-sciences space.

Very interesting article by Aiman Shalabi shared by Endpoints that there were 469 new PD-1/L1 cancer checkpoint studies launched this year. These studies require 52,000 patients to fully enroll for all these studies. Definitely a lot happening in the cancer therapy res...

During last few days there have been two interesting articles on quite different views on this topic.

In an study published in the BMJ, Courtney Davis (King's College, London) and Huseyin Naci (LSE Health) say that 39 (57%) out of 68 cancer indications approved in Europ...